Stockreport

ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

ObsEva SA - Common Shares  (OBSV) 
Last obseva sa - common shares earnings: 3/5 01:00 am Check Earnings Report
PDF Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints93.9% responder rate for 200 mg with ABT (p 56.7% responder rate for 100 mg without ABT (p Both [Read more]